Friday, August 12, 2022
    HomeHealthSTAT+: Pharmalittle: Pfizer to exit consumer-health joint venture with GSK; access to...

    STAT+: Pharmalittle: Pfizer to exit consumer-health joint venture with GSK; access to obesity drugs in U.S. remains ‘dismal’


    High of the morning to you, and a effective one it’s, regardless of the cloudy skies looming over the Pharmalot campus. In any case, the birds are nonetheless chirping and a cool breeze is wafting by. Furthermore, this marks the center of the week, which implies we’ve managed to outlive this far. And this requires celebration, sure? So please be part of us as we hoist one other cup of scrumptious stimulation. Our selection in the present day is bananas Foster. Bear in mind, no prescription is required. In the meantime, listed below are a number of objects of curiosity. Have a grand day, and drop us a line for those who hear one thing saucy. …

    Drug firms and affected person advocacy teams have been aggressively lobbying insurers to pay for weight-loss medicine, and have additionally lobbied Congress to move a invoice that has languished by means of three administrations to require Medicare to pay for the medicine. However for now, the established order has not budged, The New York Times says. Physicians argue weight problems is a persistent illness that must be handled as intensively as coronary heart illness, diabetes, hypertension, or different persistent diseases, however this not often occurs. “Entry to medicines for the therapy of weight problems is dismal on this nation,” stated Fatima Cody Stanford, an weight problems specialist at Massachusetts Common Hospital and Harvard Medical College.

    Continue to STAT+ to read the full story…

    Source link

    Related articles

    Stay Connected


    Latest posts